Anatomic, hematologic, and biochemical features of C57BL/6NCrl mice maintained on chronic oral corticosterone

Comparative Medicine

Volumn 62, Issue 5, 2012, Pages 348-360

  Cassano, Amy E ^a   White, Julie R ^a   Penraat, Kelley A ^b   Wilson, Christopher D ^a   Rasmussen, Skye ^a   Karatsoreos, Ilia N ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b Alpha Omega Veterinary Consultant Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTERONE; DRINKING WATER;

ADRENAL GLAND; ANATOMY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BLOOD EXAMINATION; CELL VACUOLE; CONTROLLED STUDY; DRUG MEGADOSE; ELECTROLYTE DISTURBANCE; GLUCOSE INTOLERANCE; LOW DRUG DOSE; MALE; METABOLIC SYNDROME X; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; OBESITY;

ADRENAL GLANDS; ANALYSIS OF VARIANCE; ANIMALS; CASE-CONTROL STUDIES; CORTICOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; GLUCOSE INTOLERANCE; LIVER; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; OBESITY; SPLEEN;

EID: 84870930493     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Bjorntorp P. 1993. Visceral obesity: a 'civilization syndrome.' Obes Res 1:206-222.
2. Bjorntorp P, Rosmond R. 2000. The metabolic syndrome - a neuroendocrine disorder? Br J Nutr 83 Suppl 1:S49-S57. (Pubitemid 30319082)
3. Bjorntorp P, Rosmond R. 2000. Obesity and cortisol. Nutrition 16:924-936.
4. Bolliger AP, Everds NE, Zimmerman KL, Moore DM, Smith SA, Barnhart K. 2010. Hematology of laboratory animals, p 860. In: Weiss DJ, Wardrop KJ, editors. Schalm's veterinary hematology, 6th ed. Ames (IA): Wiley-Blackwell.
5. Boone L, Meyer D, Cusick P, Ennulat D, Bolliger AP, Everds N, Meador V, Elliott G, Honor D, Bounous D, Jordan H. 2005. Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies. Vet Clin Pathol 34:182-188. (Pubitemid 41412481)
6. Bronnegard M, Arner P, Hellstrom L, Akner G, Gustafsson JA. 1990. Glucocorticoid receptor messenger ribonucleic acid in different regions of human adipose tissue. Endocrinology 127:1689-1696. (Pubitemid 20315227)
7. Brunner EJ, Marmot MG, Nanchahal K, Shipley MJ, Stansfeld SA, Juneja M, Alberti KG. 1997. Social inequality in coronary risk: central obesity and the metabolic syndrome. Evidence from the Whitehall II study. Diabetologia 40:1341-1349. (Pubitemid 27469676)
8. Buchman AL. 2001. Side effects of corticosteroid therapy. J Clin Gastroenterol 33:289-294. (Pubitemid 32880966)
9. Cardinali G, Decaro BM, Handler AH, Aboul-Enein M. 1964. Effect of high doses of cortisone on bone marrow cell proliferation in the Syrian hamster. Cancer Res 24:969-972.
10. Dallman MF, Pecoraro N, Akana SF, La Fleur SE, Gomez F, Houshyar H, Bell ME, Bhatnagar S, Laugero KD, Manalo S. 2003. Chronic stress and obesity: a new view of 'comfort food.' Proc Natl Acad Sci USA 100:11696-11701. (Pubitemid 37205997)
11. Dhabhar FS. 2003. Stress, leukocyte trafficking, and the augmentation of skin immune function. Ann N Y Acad Sci 992:205-217. (Pubitemid 36712197)
12. Ehrich M, Hancock S, Ward D, Holladay S, Pung T, Flory L, Hinckley J, Jortner BS. 2004. Neurologic and immunologic effects of exposure to corticosterone, chlorpyrifos, and multiple doses of tri-ortho-tolyl phosphate over a 28-day period in rats. J Toxicol Environ Health A 67:431-457. (Pubitemid 38233931)
13. Fittschen C, Bellamy JE. 1984. Prednisone-induced morphologic and chemical changes in the liver of dogs. Vet Pathol 21:399-406. (Pubitemid 14091580)
14. Gourley SL, Wu FJ, Kiraly DD, Ploski JE, Kedves AT, Duman RS, Taylor JR. 2008. Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression. Biol Psychiatry 63:353-359.
15. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. 2004. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute-American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 24:e13-e18.
16. Hautanen A, Raikkonen K, Adlercreutz H. 1997. Associations between pituitary-adrenocortical function and abdominal obesity, hyperinsulinaemia, and dyslipidaemia in normotensive males. J Intern Med 241:451-461. (Pubitemid 27315825)
17. Hoppmann J, Perwitz N, Meier B, Fasshauer M, Hadaschik D, Lehnert H, Klein J. 2010. The balance between gluco- and mineralocorticoid action critically determines inflammatory adipocyte responses. J Endocrinol 204:153-164.
18. Iancu TC, Shiloh H, Dembo L. 1986. Hepatomegaly following short-term high-dose steroid therapy. J Pediatr Gastroenterol Nutr 5:41-46. (Pubitemid 17006364)
19. Kalsbeek A, Van Der Vliet J, Buijs RM. 1996. Decrease of endogenous vasopressin release necessary for expression of the circadian rise in plasma corticosterone: a reverse microdialysis study. J Neuroendocrinol 8:299-307. (Pubitemid 26119373)
20. Karatsoreos IN, Bhagat SM, Bowles NP, Weil ZM, Pfaff DW, McEwen BS. 2010. Endocrine and physiological changes in response to chronic corticosterone: a potential model of the metabolic syndrome in mouse. Endocrinology 151:2117-2127.
21. Kour K, Bani S. 2011. Chicoric acid regulates behavioral and biochemical alterations induced by chronic stress in experimental Swiss albino mice. Pharmacol Biochem Behav 99:342-348.
22. Larsen JL, Cathey WJ, Odell WD. 1986. Primary adrenocortical nodular dysplasia, a distinct subtype of Cushing's syndrome. Case report and review of the literature. Am J Med 80:976-984. (Pubitemid 16033728)
23. Lee RS, Tamashiro KL, Yang X, Purcell RH, Harvey A, Willour VL, Huo Y, Rongione M, Wand GS, Potash JB. 2010. Chronic corticosterone exposure increases expression and decreases deoxyribonucleic acid methylation of Fkbp5 in mice. Endocrinology 151:4332-4343.
24. Lemos DR, Downs JL, Urbanski HF. 2006. Twenty-four-hour rhythmic gene expression in the rhesus macaque adrenal gland. Mol Endocrinol 20:1164-1176.
25. Li W, Bai Y, Sun K, Xue H, Wang Y, Song X, Fan X, Song H, Han Y, Hui R. 2009. Patients with metabolic syndrome have prolonged corrected QT interval (QTc). Clin Cardiol 32:E93-E99.
26. Lien YH, Huang HP, Chang PH. 2006. Iatrogenic hyperadrenocorticism in 12 cats. J Am Anim Hosp Assoc 42:414-423.
27. Macfarlane DP, Forbes S, Walker BR. 2008. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol 197:189-204. (Pubitemid 351696232)
28. Magarinos AM, Orchinik M, McEwen BS. 1998. Morphological changes in the hippocampal CA3 region induced by noninvasive glucocorticoid administration: a paradox. Brain Res 809:314-318. (Pubitemid 29005389)
29. Mancini T, Doga M, Mazziotti G, Giustina A. 2004. Cushing's syndrome and bone. Pituitary 7:249-252. (Pubitemid 43115860)
30. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. 2001. A transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170. (Pubitemid 33150673)
31. Montague CT, O'Rahilly S. 2000. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 49:883-888. (Pubitemid 30349408)
32. Morton NM, Densmore V, Wamil M, Ramage L, Nichol K, Bunger L, Seckl JR, Kenyon CJ. 2005. A polygenic model of the metabolic syndrome with reduced circulating and intraadipose glucocorticoid action. Diabetes 54:3371-3378. (Pubitemid 43334325)
33. Nieuwenhuizen AG, Rutters F. 2008. The hypothalamic-pituitary-adrenal axis in the regulation of energy balance. Physiol Behav 94:169-177. (Pubitemid 351615426)
34. Nuotio-Antar AM, Hachey DL, Hasty AH. 2007. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice. Am J Physiol Endocrinol Metab 293:E1517-E1528. (Pubitemid 350255101)
35. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR, Mullins JJ. 2004. Metabolic syndrome without obesity: hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 101:7088-7093. (Pubitemid 38596447)
36. Peeke PM, Chrousos GP. 1995. Hypercortisolism and obesity. Ann N Y Acad Sci 771:665-676. (Pubitemid 26077444)
37. Pellet H, Guerrier D, Thonnerieux M, Vigier M. 1975. [Influence of the pituitary-adrenal axis on the brown fat tissue of the rat and golden hamster] Bull Assoc Anat (Nancy) 59:479-488. [Article in French].
38. Pung T, Zimmerman K, Klein B, Ehrich M. 2003. Corticosterone in drinking water: altered kinetics of a single oral dose of corticosterone and concentrations of plasma sodium, albumin, globulin, and total protein. Toxicol Ind Health 19:171-182. (Pubitemid 40193715)
39. Putignano P, Kaltsas GA, Korbonits M, Jenkins PJ, Monson JP, Besser GM, Grossman AB. 2000. Alterations in serum protein levels in patients with Cushing's syndrome before and after successful treatment. J Clin Endocrinol Metab 85:3309-3312.
40. Rangon CM, Fortes S, Lelievre V, Leroux P, Plaisant F, Joubert C, Lanfumey L, Cohen-Salmon C, Gressens P. 2007. Chronic mild stress during gestation worsens neonatal brain lesions in mice. J Neurosci 27:7532-7540. (Pubitemid 47066578)
41. Reaven GM. 1988. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607. (Pubitemid 19004941)
42. Rebuffe-Scrive M, Walsh UA, McEwen B, Rodin J. 1992. Effect of chronic stress and exogenous glucocorticoids on regional fat distribution and metabolism. Physiol Behav 52:583-590.
43. Rogers WA, Ruebner BH. 1977. A retrospective study of probable glucocorticoid-induced hepatopathy in dogs. J Am Vet Med Assoc 170:603-606. (Pubitemid 8058278)
44. Saunders D, Adelstein RS, Conti MA, Zhang Y. 2010. Mouse urine collection using single animal model. J Am Assoc Lab Anim Sci 49:686.
45. Schaer M, Ginn PE. 1999. Iatrogenic Cushing's syndrome and steroid hepatopathy in a cat. J Am Anim Hosp Assoc 35:48-51. (Pubitemid 129761583)
46. Seckl JR, Walker BR. 2001. Minireview: 11β-hydroxysteroid dehydrogenase type 1 - a tissue-specific amplifier of glucocorticoid action. Endocrinology 142:1371-1376. (Pubitemid 32299662)
47. Smart JL, Tolle V, Low MJ. 2006. Glucocorticoids exacerbate obesity and insulin resistance in neuron-specific proopiomelanocortin-deficient mice. J Clin Invest 116:495-505. (Pubitemid 43228367)
48. Smets P, Meyer E, Maddens B, Daminet S. 2010. Cushing's syndrome, glucocorticoids, and the kidney. Gen Comp Endocrinol 169:1-10.
49. Stenzel-Poore MP, Cameron VA, Vaughan J, Sawchenko PE, Vale W. 1992. Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. Endocrinology 130:3378-3386.
50. Stockham SL, Scott MA. 2008. Fundamentals of veterinary clinical pathology. Oxford (UK): Blackwell Publishing.
51. Taki K, Nishio K, Hamajima N, Niwa T. 2008. Metabolic syndrome defined by new criteria in Japanese is associated with increased liver enzymes and C-reactive protein. Nagoya J Med Sci 70:1-9.
52. Traslavina RP, King EJ, Loar AS, Riedel ER, Garvey MS, Ricart-Arbona R, Wolf FR, Couto SS. 2010. Euthanasia by CO inhalation affects potassium levels in mice. J Am Assoc Lab Anim Sci 49:316-322.
53. Ulrich-Lai YM, Figueiredo HF, Ostrander MM, Choi DC, Engeland WC, Herman JP. 2006. Chronic stress induces adrenal hyperplasia and hypertrophy in a subregion-specific manner. Am J Physiol Endocrinol Metab 291:E965-E973.
54. Verma P, Hellemans KG, Choi FY, Yu W, Weinberg J. 2010. Circadian phase and sex effects on depressive-anxiety-like behaviors and HPA axis responses to acute stress. Physiol Behav 99:276-285.
55. Wajchenberg BL. 2000. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21:697-738. (Pubitemid 32113289)
56. Wolf G. 2002. Glucocorticoids in adipocytes stimulate visceral obesity. Nutr Rev 60:148-151. (Pubitemid 34525610)